Biovica International Third Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Biovica International (STO:BIOVIC B) Third Quarter 2025 Results
Key Financial Results
- Revenue: kr2.35m (up 118% from 3Q 2024).
- Net loss: kr22.8m (loss narrowed by 17% from 3Q 2024).
- kr0.23 loss per share (improved from kr0.43 loss in 3Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Biovica International EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 43%. Earnings per share (EPS) exceeded analyst estimates by 19%.
Looking ahead, revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Sweden.
Performance of the Swedish Biotechs industry.
The company's shares are down 36% from a week ago.
Risk Analysis
We should say that we've discovered 5 warning signs for Biovica International (3 are significant!) that you should be aware of before investing here.
If you're looking to trade Biovica International, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentValuation is complex, but we're here to simplify it.
Discover if Biovica International might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:BIOVIC B
Biovica International
A biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the United States of America.
Medium-low and good value.
